Suvorexant
CAS 1030377-33-3 6 FDA-DMF suppliersSmall Molecule
Overview
Suvorexant is a dual orexin receptor antagonist used for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. It works by inhibiting the action of orexins, neuropeptides that play a role in promoting wakefulness.
Patent & exclusivity (US)
Per the FDA Orange Book (4 approved US products), the latest listed US patent on Suvorexant expires 28 May 2033. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
NeurologySleep Disorders
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.